CA3211248A1 - Novel darpin based cd33 engagers - Google Patents

Novel darpin based cd33 engagers

Info

Publication number
CA3211248A1
CA3211248A1 CA3211248A CA3211248A CA3211248A1 CA 3211248 A1 CA3211248 A1 CA 3211248A1 CA 3211248 A CA3211248 A CA 3211248A CA 3211248 A CA3211248 A CA 3211248A CA 3211248 A1 CA3211248 A1 CA 3211248A1
Authority
CA
Canada
Prior art keywords
ankyrin repeat
protein
binding
binding protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3211248A
Other languages
English (en)
French (fr)
Inventor
Nina RESCHKE
Christian REICHEN
Bernd Schlereth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Partners AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3211248A1 publication Critical patent/CA3211248A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ignition Installations For Internal Combustion Engines (AREA)
  • Valve Device For Special Equipments (AREA)
  • Electroluminescent Light Sources (AREA)
CA3211248A 2021-03-09 2022-03-09 Novel darpin based cd33 engagers Pending CA3211248A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163158539P 2021-03-09 2021-03-09
US63/158,539 2021-03-09
US202163172818P 2021-04-09 2021-04-09
US63/172,818 2021-04-09
US202163265179P 2021-12-09 2021-12-09
US63/265,179 2021-12-09
PCT/IB2022/052120 WO2022190010A1 (en) 2021-03-09 2022-03-09 Novel darpin based cd33 engagers

Publications (1)

Publication Number Publication Date
CA3211248A1 true CA3211248A1 (en) 2022-09-15

Family

ID=80933410

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3211248A Pending CA3211248A1 (en) 2021-03-09 2022-03-09 Novel darpin based cd33 engagers

Country Status (6)

Country Link
US (1) US20240317852A1 (cg-RX-API-DMAC7.html)
EP (1) EP4304730A1 (cg-RX-API-DMAC7.html)
JP (1) JP7869804B2 (cg-RX-API-DMAC7.html)
AU (1) AU2022231913A1 (cg-RX-API-DMAC7.html)
CA (1) CA3211248A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022190010A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
WO2024251628A1 (en) * 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
WO2025163082A1 (en) * 2024-01-31 2025-08-07 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
EP3514169B1 (en) 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
SG11201408196RA (en) 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
US9458211B1 (en) 2015-04-02 2016-10-04 Molecular Partners Ag Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
MY196882A (en) 2016-09-22 2023-05-08 Molecular Partners Ag Recombinant binding proteins and their use

Also Published As

Publication number Publication date
JP7869804B2 (ja) 2026-06-03
US20240317852A1 (en) 2024-09-26
AU2022231913A1 (en) 2023-09-28
EP4304730A1 (en) 2024-01-17
JP2024508969A (ja) 2024-02-28
AU2022231913A9 (en) 2024-01-25
WO2022190010A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
US20240150475A1 (en) Novel darpin based cd123 engagers
US20240317852A1 (en) Novel darpin based cd33 engagers
TWI825086B (zh) Her3抗原結合分子
US20250074994A1 (en) Novel darpin based cd70 engagers
KR102290592B1 (ko) Her2에 대항하는 적어도 두 개 이상의 반복 도메인을 포함하는 결합 단백질
US20220242973A1 (en) Recombinant fap binding proteins and their use
KR20220086554A (ko) Her3 항원-결합 분자를 사용한 암의 치료 및 예방
US11834504B2 (en) DARPin based multi-specific t-cell engagers
EP4724473A1 (en) Recombinant cd47 binding proteins and their use
WO2024251628A1 (en) Recombinant cd16a binding proteins and their use
US20240108746A1 (en) Novel slow-release prodrugs
CN121263440A (zh) 重组cd2结合蛋白及其用途
CN117242100A (zh) 基于DARPin的新型CD70接合物
CN117255803A (zh) 基于DARPin的新型CD33接合物
CN117177996A (zh) 基于DARPin的新型CD123接合物
CN116802213A (zh) 重组cd3结合蛋白及其用途
HK40026637B (en) Her3 antigen-binding molecules
HK40026637A (en) Her3 antigen-binding molecules

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250225

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250225

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250225

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260420

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260526